Systagenix Wound Management announces head of EMEA to boost international market
This article was originally published in Clinica
Executive Summary
Systagenix Wound Management (London, UK), formerly Ethicon's wound care division, has appointed Frank DiLazzaro as president of Europe, Middle East and Africa (EMEA). His remit is to strengthen the current regional management teams and significantly boost the uptake of Systagenix's products in these markets. Mr DiLazzaro has a strong background in wound care products. He is credited with playing a key role in the transformation of the negative pressure wound therapy business at Kinetic Concepts. His experience in both public and private equity settings and his academic background in economics are expected to be valuable skills in helping Systagenix build its international market.
You may also be interested in...
Asia Regulatory Forum Update
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia adopts interim device authorisation regulation
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
Canada takes action to increase more adverse event reporting
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.